BRS101
Idiopathic Pulmonary Fibrosis
Phase 1Active
Key Facts
About BreStem Therapeutics
BreStem Therapeutics is pioneering lung regeneration therapies from its base in San Diego. The company's core innovation is the isolation and expansion of intrinsic lung spheroid cells (LSCs), with its lead autologous candidate BRS101 cleared for clinical trials in idiopathic pulmonary fibrosis. With a second, cell-free exosome program in preIND development and a founding team led by a renowned academic researcher, BreStem aims to address a high-mortality market with significant unmet need. The company is privately held and appears to be in a pre-revenue, clinical-stage development phase.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| BIO 300 | Humanetics Corp. | Research |
| Undisclosed | Biossil | Phase 2/3 |
| KITCL27 | Kither Biotech | Preclinical |
| T03 | Treamid Therapeutics | Phase 1 |
| ING-006 | Innosphera Pharma | Preclinical |
| MNM‑siRNA IPF | Interna TX | Preclinical |
| Pirfenidone | Gyre Therapeutics | Marketed |
| PIPE-791 | Contineum Therapeutics | Phase 1 |